Anemia in diabetic nephropathy: Prevalence, clinical and pathophysiological aspects

Terapevticheskii Arkhiv

Volumn 80, Issue 6, 2008, Pages 41-47

  Shestakova, M V ^a   Martynov, S A ^a   Ilyin, A V ^a   Knyazeva, A P ^a   Shamkhalova, M Sh ^a   Trubitsyna, N P ^a  

^a NONE

Author keywords

Anemia; Chronic glomerulonephritis; Diabetes mellitus; Diabetic nephropathy; Erythropoietin

Indexed keywords

HEMOGLOBIN;

ADULT; ANEMIA; ARTICLE; BLOOD; COMPARATIVE STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PREVALENCE; RUSSIAN FEDERATION;

ADULT; ANEMIA; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RUSSIA; SEVERITY OF ILLNESS INDEX;

EID: 48349134204     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. King H., Aubert R. E., Herman W. H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabet. Care 1998; 21: 1414-1431.
2. Russian source
3. Russian source
4. USRDS 2007 Annual Data Report, volume i. Atlas of chronic kidney disease and end-stage renal disease in United States. http://www.usrds.org/
5. Thomas M., MacIsaac J., Tsalamandris C. et al. Anemia hi patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 2004; 89 (9): 4359-4363.
6. Thomas M., MacIsaac J., Tsalamandris C. et al. The burden of anemia in type 2 diabetes and role of nephropathy: a cross-sectional audit. Nephrol. Dial. Transplant. 2004; 19: 1792-1797.
7. El-Achkar T. M., Ohmit S. K, McCullough P. A. et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005; 67: 1483-1488.
8. Thomas M., MacIsaac R. J., Power D., Jerums G. Unrecognized anemia in patients with diabetes. Diabet. Care 2003; 26 (4): 1164-1169.
9. Broon J. Anemia in diabetic renal disease: and underestimated risk factor. Acta Diabetol. 2002; 39: S2.
10. Stevens P. E., O'Donoghue J., Lameire N. R. Anemia in patients with diabetes: unrecognized, undetected and untreated? Curr. Med. Res. Opin. 2003; 19 (5): 395-401.
11. Mohanram A., Zhang Z., Shaninfar S. et al. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int. 2004; 66: 1131-1138.
12. Thomas M. Anemia in diabetes: marker of mediator of microvascular disease. Nat. Clin. Pract. Nephrol. 2007; 1 (3): 20-30.
13. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation classification and stratification. Am. J. Kidney Dis. 2002; 39 (suppl. 1); SI-8266.
14. Cockroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
15. World Health Organization. Nutritional anemia: Report of WHO Scientific Group. Geneva; 1968.
16. National Kidney Foundation: K/DOQI clinical practice guidelines and clinical practice recommendations for anemia of chronic kidney disease. Am. J. Kidney Dis. 2006; 47 (suppl. 3): S1-S145.
17. Macdougall I. C., Eckard K-U., Locatelli F. Latest US DOQI anemia guidelines update - what are the implications for Europe? Nephrol. Dial. Transplant. 2007; 22: 2738-2742.
18. Russian source
19. Russian source
20. Russian source
21. White K. E., Marshall S. M., Bilous W. Are glomerular volume differences between type 1 and type 2 diabetic patients pathologically significant? Diabetologia 2007; 50 (5): 906-912.
22. Lorber D., Reddan D. Clinical characteristics of chronic kidney disease patients with and without diabetes: a subanalysis of the PAERI study. Clin. Nephrol. 2006; 66: 11-16.
23. Russian source
24. Russian source
25. Artunc F., Risler A. Serum erythropoietin concentrations and responses to anemia in patients with or without chronic kidney disease. Nephrol. Dial. Transplant. 2007; 22: 2900-2908.
26. Bosman D. R., Winkler A. S., Marsden J. T. et al. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabet. Care 2001; 24 (3): 495-499.
27. Fehr T., Ammann P., Garzoni D. et al. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int. 2004; 66: 1206-1244.
28. White K. E., Bilous R. W. Type 2 diabetic patients with nephropathy show structural functional relationships that are similar type 1 disease. J. Am. Soc. Nephrol. 2000; 11: 1667-1673.
29. Bosman D. R., Osborne C. A., Marsden J. T. et al. Erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy and non-diabetic chronic renal failure. Diabet. Med. 2002; 19: 65-69.
30. Catrina S.-B., Okamoto K., Pereira T. et al. Hyperglycemia regulates hypoxia-inducible factor-1α protein stability and function. Diabetes 2004; 53: 3226-3232.
31. 1c levels in patients with chronic renal failure on heamodialysis. Intern. Med. 1998; 37: 826-830.
32. Russian source
33. MacDougall I. The role of ACE inhibitor and angiotensin II receptor blockers in the response to epoetin. Nephrol. Dial. Transplant. 1999; 14: 1836-1841.
34. Pratt M. C., Lewis-Barnard N. J., Walker R. J. et al. Effect of angiotensin converting enzyme inhibitors on erythropoietin concentration in healthy volunteers. Br. J. Clin. Phannacol. 1992; 34: 363-365.
35. Stevens P. Optimizing renal anemia management - benefits of early referral and treatment. Nephrol. Dial. Transplant. 2005; 20 (suppl. 8): viii22-viii26.
36. Ritz E., Laville M., Bilous R. W. et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am. J. Kidney Dis. 2007; 49: 194-207.
37. Singh A. K., Szczech L., Tang K. L. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 2006; 335: 2085-2098.